Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
86 hedge funds and large institutions have $223M invested in Paratek Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 37 increasing their positions, 13 reducing their positions, and 13 closing their positions.
185% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 13
31% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $1.42M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less funds holding
Funds holding: 90 → 86 (-4)
9% less capital invested
Capital invested by funds: $245M → $223M (-$21.7M)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.96M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.84M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.22M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.11M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$955K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$8M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.04M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.74M |
| 4 |
Millennium Management
New York
|
-$1.72M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.7M |
PRTK Hedge Fund Activity: Q3 2016 in Review
86 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2016, worth a combined $223M — down 8.9% from $245M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PRTK and 9 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 37 added.
The largest buyer was Vanguard Group, adding an estimated $1.96M. The largest seller was BVF Inc, exiting entirely with an estimated $8M sold.
- 86 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2016, down from 90 in Q2 2016.
- Funds reported $223M of Paratek Pharmaceuticals, Inc. stock for Q3 2016, down 8.9% quarter-over-quarter.
- 9 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2016 and 13 closed out, a net change of -4 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2016 was Vanguard Group, an estimated $1.96M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2016 was BVF Inc, an estimated $8M sold.
Based on aggregated 13F filings for Q3 2016.